A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
- Resource Type
- Article
- Source
- In
Gynecologic Oncology July 2015 138(1):30-35 - Subject
- Language
- ISSN
- 0090-8258